The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Glucocorticoid corticosteroids for Duchenne muscular dystrophy
Abstract
BACKGROUND: Duchenne muscular dystrophy is the most common muscular dystrophy of childhood. This incurable disease is characterised by muscle wasting and loss of walking ability leading to complete wheelchair dependence by 13 years of age. Prolongation of walking is one of the major aims of treatment. OBJECTIVES: The aim of this review was to assess whether glucocorticoid corticosteroids stabilize or improve muscle strength and walking in boys with DMD. SEARCH STRATEGY: We searched the Cochrane Neuromuscular Disease Group specialised register (October 2003) using the term 'Duchenne muscular dystrophy'. We also searched MEDLINE (January 1966 to October 2003), EMBASE (January 1980 to October 2003), CINAHL and LILACS (January 1982 to October 2003). We wrote to authors of published studies and other experts in this disease to help identify other trials, checked the references in the identified trials and handsearched the abstracts of relevant journals. SELECTION CRITERIA: Types of studies: randomised or quasi-randomised trials. TYPES OF PARTICIPANTS: all patients with a definite diagnosis of Duchenne muscular dystrophy. Types of interventions: glucocorticoids such as prednisone, prednisolone, deflazacort or others, with a minimum treatment period of three months. PRIMARY OUTCOME MEASURE: prolongation of walking (independent walking without long leg calipers). SECONDARY OUTCOME MEASURES: strength outcome measures, manual muscle strength testing using Medical Research Council strength scores, functional outcome measures and adverse events. DATA COLLECTION AND ANALYSIS: We identified five randomised controlled trials that met the inclusion criteria for our review. Two reviewers independently selected the trials for the review and assessed methodological quality. Data extraction and inputting were double-checked. PRIMARY OUTCOME MEASURE: data from one small study used prolongation of walking as an outcome measure and did not show significant benefit. SECONDARY OUTCOME MEASURES: The meta-analysis of the results from three randomised controlled trials showed that glucocorticoid corticosteroids improved muscle strength and function over six months. Improvements were seen in time taken to rise from the floor (Gowers' time), nine metres walking time, four-stair climbing time, ability to lift weights, leg function grade and forced vital capacity. One randomised controlled trial showed that glucocorticoid corticosteroids stabilize muscle strength and function for up to two years. The most effective prednisolone regime appears to be 0.75 mg/kg/day. Not enough data were available to compare efficacy of prednisone with deflazacort.Adverse effects: Excessive weight gain, behavioural abnormalities, cushingoid appearance and excessive hair growth were all more common with glucocorticoid corticosteroids than placebo. Long-term adverse effects of glucocorticoid therapy could not be evaluated because of the short-term duration of the randomised studies.Non-randomised studies: a number of non-randomised studies with important efficacy and adverse effects data are tabulated and discussed. REVIEWERS' CONCLUSIONS: There is evidence from randomised controlled studies that glucocorticoid corticosteroid therapy in Duchenne muscular dystrophy improves muscle strength and function in the short-term (six months to two years). The most effective prednisolone regime appears to be 0.75 mg/kg/day. In the short term, adverse effects were significantly more common but not clinically severe. Long-term benefits and hazards of glucocorticoid treatment cannot be evaluated from the currently published randomised studies. Non-randomised studies support the conclusions of functional benefits but also indicate clinically significant adverse effects of long-term treatment. These benefits and adverse effects have implications for future research studies and clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
(1958) · Journal of the American Pharmaceutical Association (Scientific ed.) · doi:10.1002/jps.3030470133 · Cited by 2,489
Emery, A. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07815-7 · Cited by 1,667
Dystrophin protects the sarcolemma from stresses developed during muscle contraction
Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M., & Sweeney, H. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3710 · Cited by 1,526
Population frequencies of inherited neuromuscular diseases—A world survey
Emery, A. E. H. (1991) · Neuromuscular Disorders · doi:10.1016/0960-8966(91)90039-u · Cited by 1,448
Eagle, M., Baudouin, S. V., Chandler, C., Giddings, D. R., Bullock, R., & Bushby, K. (2002) · Neuromuscular Disorders · doi:10.1016/s0960-8966(02)00140-2 · Cited by 1,009
Koenig, M., Beggs, A. H., Moyer, M., Scherpf, S., Heindrich, K., Bettecken, T., Meng, G., Müller, C. R., Lindlöf, M., Kääriäinen, H. A., et al. (1989) · Europe PMC (PubMed Central) · Cited by 961
Arahata, K., & Engel, A. G. (1984) · Annals of Neurology · doi:10.1002/ana.410160206 · Cited by 630
Clinical trial in duchenne dystrophy. I. The design of the protocol
Brooke, M. H., Griggs, R. C., Mendell, J. R., Fenichel, G. M., Shumate, J. B., & Pellegrino, R. J. (1981) · Muscle & Nerve · doi:10.1002/mus.880040304 · Cited by 564
Randomized, Double-Blind Six-Month Trial of Prednisone in Duchenne's Muscular Dystrophy
Mendell, J. R., Moxley, R. T., Griggs, R. C., Brooke, M. H., Fenichel, G. M., Miller, J. P., King, W., Signore, L., Pandya, S., Florence, J., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906153202405 · Cited by 520
Dubowitz, V. (2015) · Muscular Dystrophy 1976 · doi:10.1159/000400687 · Cited by 483
Porter, J. D. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.3.263 · Cited by 442
Brooke, M. H., Fenichel, G. M., Griggs, R. C., Mendell, J. R., Moxley, R., Miller, J. P., & Province, M. A. (1983) · Muscle & Nerve · doi:10.1002/mus.880060204 · Cited by 353
Dystrophin–glycoprotein complex: Its role in the molecular pathogenesis of muscular dystrophies
Matsumura, K., & Campbell, K. P. (1994) · Muscle & Nerve · doi:10.1002/mus.880170103 · Cited by 311
Beenakker, E. A. C., van der Hoeven, J. H., Fock, J. M., & Maurits, N. M. (2001) · Neuromuscular Disorders · doi:10.1016/s0960-8966(01)00193-6 · Cited by 305
Bushby, K., Muntoni, F., & Bourke, J. P. (2003) · Neuromuscular Disorders · doi:10.1016/s0960-8966(02)00213-4 · Cited by 300
Quantitation of muscle function in children: A prospective study in duchenne muscular dystrophy
Scott, O. M., Hyde, S. A., Goddard, C., & Dubowitz, V. (1982) · Muscle & Nerve · doi:10.1002/mus.880050405 · Cited by 298
MUNSAT, T. L. (1979) · Neurology · doi:10.1212/wnl.29.4.530-a · Cited by 292
Gomez-Merino, E., & Bach, J. R. (2002) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/00002060-200206000-00003 · Cited by 292
The pathology of the heart in progressive muscular dystrophy: Epimyocardial fibrosis
Frankel, K. A., & Rosser, R. J. (1976) · Human Pathology · doi:10.1016/s0046-8177(76)80053-6 · Cited by 287
Griggs, R. C. (1991) · Archives of Neurology · doi:10.1001/archneur.1991.00530160047012 · Cited by 279
Long‐term benefit from prednisone therapy in Duchenne muscular dystrophy
Fenichel, G. M., Florence, J. M., Pestronk, A., Mendell, J. R., Moxley, R. T., Griggs, R. C., Brooke, M. H., Miller, J. P., Robison, J., King, W., et al. (1991) · Neurology · doi:10.1212/wnl.41.12.1874 · Cited by 263
Bonifati, M. D., Ruzza, G., Bonometto, P., Berardinelli, A., Gorni, K., Orcesi, S., Lanzi, G., & Angelini, C. (2000) · Muscle & Nerve · doi:10.1002/1097-4598(200009)23:9<1344::aid-mus4>3.0.co;2-f · Cited by 231
Deflazacort treatment of Duchenne muscular dystrophy
Biggar, W. D., Gingras, M., Fehlings, D. L., Harris, V. A., & Steele, C. A. (2001) · The Journal of Pediatrics · doi:10.1067/mpd.2001.109601 · Cited by 214
PREDNISONE IN DUCHENNE MUSCULAR DYSTROPHY
Drachman, D. B., Toyka, K. V., & Myer, E. (1974) · The Lancet · doi:10.1016/s0140-6736(74)90071-3 · Cited by 212
Clinical Pharmacokinetics of Prednisone and Prednisolone
Frey, B. M., & Frey, F. J. (1990) · Clinical Pharmacokinetics · doi:10.2165/00003088-199019020-00003 · Cited by 197
Griggs, R. C., Moxley, R. T., Mendell, J. R., Fenichel, G. M., Brooke, M. H., Pestronk, A., Miller, J. P., Cwik, V. A., Pandya, S., Robison, J., et al. (1993) · Neurology · doi:10.1212/wnl.43.3_part_1.520 · Cited by 196
Jeppesen, J., Green, A., Steffensen, B. F., & Rahbek, J. (2003) · Neuromuscular Disorders · doi:10.1016/s0960-8966(03)00162-7 · Cited by 192
The molecular basis of activity-induced muscle injury in Duchenne muscular dystrophy
Petrof, B. J. (1998) · Molecular and Cellular Biochemistry · doi:10.1023/a:1006812004945 · Cited by 187
Corticosteroid Treatment and Functional Improvement in Duchenne Muscular Dystrophy: Long-Term Effect
Balaban, B., Matthews, D. J., Clayton, G. H., & Carry, T. (2005) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/01.phm.0000184156.98671.d0 · Cited by 184
Clinical Investigation of Duchenne Muscular Dystrophy: Interesting Results in a Trial of Prednisone
Brooke, M. H., Fenichel, G. M., Griggs, R. C., Mendell, J. R., Moxley, R. T., Miller, J. P., Kaiser, K. K., Florence, J. M., Pandya, S., & Signore, L. (1987) · Archives of Neurology · doi:10.1001/archneur.1987.00520200016010 · Cited by 157
Deflazacort in Duchenne dystrophy: Study of long‐term effect
Angelini, C. I., Pegoraro, E., Turella, E., Intino, M. T., Pini, A., & Costa, C. (1994) · Muscle & Nerve · doi:10.1002/mus.880170405 · Cited by 152
Steroid Treatment and the Development of Scoliosis in Males with Duchenne Muscular Dystrophy
Alman, B. A., Raza, S. N., & Biggar, W. D. (2004) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-200403000-00009 · Cited by 152
Engel, A. G., & Biesecker, G. (1982) · Annals of Neurology · doi:10.1002/ana.410120314 · Cited by 151
Prednisone Treatment in Duchenne Muscular Dystrophy: Long-term Benefit
DeSilva, S., Drachman, D. B., Mellits, D., & Kuncl, R. W. (1987) · Archives of Neurology · doi:10.1001/archneur.1987.00520200022012 · Cited by 150
Bushby, K. M. D., Francesco Muntoni, A., Urtizberea, A., Hughes, R. A., & Griggs, R. C. (2004) · Neuromuscular Disorders · doi:10.1016/j.nmd.2004.05.006 · Cited by 149
Porter, J. D., Merriam, A. P., Leahy, P. S., Gong, B., & Khanna, S. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg197 · Cited by 145
Cardioprotection for Duchenne’s muscular dystrophy
Ishikawa, Y., Bach, J. R., & Minami, R. (1999) · American Heart Journal · doi:10.1016/s0002-8703(99)70414-x · Cited by 139
High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy
Connolly, A. M., Schierbecker, J. R., Renna, R., & Florence, J. M. (2002) · Neuromuscular Disorders · doi:10.1016/s0960-8966(02)00180-3 · Cited by 138
CLINICAL FEATURES AND CLASSIFICATION OF THE MUSCULAR DYSTROPHIES
Gardner‐Medwin, D. (1980) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a071623 · Cited by 134
Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy
Silversides, C. K., Webb, G. D., Harris, V. A., & Biggar, D. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)03429-x · Cited by 133
Early prednisone treatment in Duchenne muscular dystrophy
Merlini, L., Cicognani, A., Malaspina, E., Gennari, M., Gnudi, S., Talim, B., & Franzonı, E. (2002) · Muscle & Nerve · doi:10.1002/mus.10319 · Cited by 131
Steroid Therapy and Cardiac Function in Duchenne Muscular Dystrophy
Markham, L. W., Spicer, R., Khoury, P. R., Wong, B. L. Y., Mathews, K. D., & Cripe, L. H. (2005) · Pediatric Cardiology · doi:10.1007/s00246-005-0909-4 · Cited by 125
Fenichel, G. M., Mendell, J. R., Moxley, R. T., Griggs, R. C., Brooke, M. H., Miller, J. P., Pestronk, A., Robison, J., King, W., Signore, L., et al. (1991) · Archives of Neurology · doi:10.1001/archneur.1991.00530180027012 · Cited by 123
Vertebral Fractures in Boys with Duchenne Muscular Dystrophy
Bothwell, J. E., Gordon, K., Dooley, J. M., MacSween, J., Cummings, E. A., & Salisbury, S. R. (2003) · Clinical Pediatrics · doi:10.1177/000992280304200408 · Cited by 120
Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols
Biggar, W., Politano, L., Harris, V. A., Passamano, L., Vajsar, J., Alman, B. A., Palladino, A., Comi, L. I., & Nigro, G. (2004) · Neuromuscular Disorders · doi:10.1016/j.nmd.2004.05.001 · Cited by 119
Clinical usefulness of urinary 3-methylhistidine excretion in indicating muscle protein breakdown.
Elia, M., Carter, A., Bacon, S., Winearls, C. G., & Smith, R. (1981) · BMJ · doi:10.1136/bmj.282.6261.351 · Cited by 112
Cardiomyopathy in muscular dystrophies
Muntoni, F. (2003) · Current Opinion in Neurology · doi:10.1097/00019052-200310000-00003 · Cited by 112
Steroids in duchenne muscular dystrophy — Deflazacort trial
Mesa, L., Dubrovsky, A. L., Corderí, J., Marco, P., & Flores, D. (1991) · Neuromuscular Disorders · doi:10.1016/0960-8966(91)90099-e · Cited by 110
Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis
Yılmaz, Ö., Karaduman, A., & Topaloğlu, H. (2004) · European Journal of Neurology · doi:10.1111/j.1468-1331.2004.00866.x · Cited by 109
Kissel, J. T., Burrow, K. L., Rammohan, K. W., Mendell, J. R., & the CIDD Study Group (1991) · Neurology · doi:10.1212/wnl.41.5.667 · Cited by 100
Intermittent Prednisone Therapy in Duchenne Muscular Dystrophy: A Randomized Controlled Trial
Beenakker, E. A. C., Fock, J. M., Tol, M. J. V., Maurits, N. M., Koopman, H. M., Brouwer, O. F., & van der Hoeven, J. H. (2005) · Archives of Neurology · doi:10.1001/archneur.62.1.128 · Cited by 100
Diagnostic criteria for neuromuscular disorders
Flanigan, K. M. (1998) · American Journal of Medical Genetics · Cited by 99
Beenakker, E. A. C., Maurits, N. M., Fock, J. M., Brouwer, O. F., & van der Hoeven, J. H. (2005) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2005.06.004 · Cited by 97
Corticosteroids in Duchenne Muscular Dystrophy: A Reappraisal
Wong, B. L. Y., & Christopher, C. (2002) · Journal of Child Neurology · doi:10.1177/088307380201700306 · Cited by 85
Steroids in Duchenne muscular dystrophy: from clinical trials to genomic research
Muntoni, F., Fisher, I. B., Morgan, J. E., & Abraham, D. (2002) · Neuromuscular Disorders · doi:10.1016/s0960-8966(02)00101-3 · Cited by 81
Anderson, J. E., Weber, M., & Vargas, C. (2000) · Cell Transplantation · doi:10.1177/096368970000900411 · Cited by 81
Calcium influx inhibition by steroids and analogs in C2C12 skeletal muscle cells
Passaquin, A., Lhôte, P., & Rüegg, U. T. (1998) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702036 · Cited by 78
Low-dose prednisolone treatment in Duchenne and Becker muscular dystrophy
Backman, E. J., & Henriksson, K. G. (1995) · Neuromuscular Disorders · doi:10.1016/0960-8966(94)00048-e · Cited by 78
Prednisone in Duchenne dystrophy
Dubowitz, V. (1991) · Neuromuscular Disorders · doi:10.1016/0960-8966(91)90019-o · Cited by 77
cDNA microarray analysis of individual Duchenne muscular dystrophy patients
Noguchi, S., Tsukahara, T., Fujita, M., Kurokawa, R., Tachikawa, M., Toda, T., Tsujimoto, A., Arahata, K., & Nishino, I. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg065 · Cited by 77
Cyclosporine increases muscular force generation in Duhenne muscular dystrophy
Sharma, K. R., Mynhier, M. A., & Miller, R. G. (1993) · Neurology · doi:10.1212/wnl.43.3_part_1.527 · Cited by 75
PROLONGATIÓN OF WALKING IN DUCHENNE MUSCULAR DYSTROPHY WITH LIGHTWEIGHT ORTHOSES; REVIEW OF 57 CASES
Heckmatt, J. Z., Dubowitz, V., Hyde, S. A., Florence, J., Gabain, A. C., & Thompson, N. (1985) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.1985.tb03763.x · Cited by 73
Rodillo, E., Fernandez-Bermejo, E., Heckmatt, J. Z., & Dubowitz, V. (1988) · Journal of Child Neurology · doi:10.1177/088307388800300407 · Cited by 70
Prednisone can protect against exercise-induced muscle damage
Jacobs, S. C. J. M., Bootsma, A. L., Willems, P. W. A., B�r, P. D. P. R., & Wokke, J. H. J. (1996) · Journal of Neurology · doi:10.1007/bf00869001 · Cited by 68
Quinlivan, R. C. M., Roper, H., Davie, M. W. J., Shaw, N. J., McDonagh, J. E. R., & Bushby, K. M. D. (2004) · Neuromuscular Disorders · doi:10.1016/j.nmd.2004.09.009 · Cited by 66
Kinali, M., Mercuri, E. M., Main, M. L., Francesco Muntoni, A., & Dubowitz, V. (2002) · Neuromuscular Disorders · doi:10.1016/s0960-8966(02)00097-4 · Cited by 66
Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study
Reitter, B. F. (1995) · Brain and Development · doi:10.1016/0387-7604(95)00015-1 · Cited by 66
Deflazacort for the treatment of Duchenne Dystrophy: A systematic review
Campbell, C., & Jacob, P. J. (2003) · BMC Neurology · doi:10.1186/1471-2377-3-7 · Cited by 65
Bracing for Ambulation in Childhood Progressive Muscular Dystrophy
Spencer, G. E., & Vignos, P. J. (1962) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-196244020-00002 · Cited by 63
Matsumura, K., Ohlendieck, K., Ionasescu, V. V., Tomé, F. M. S., Nonaka, I., Burghes, A. H. M., Mora, M., Kaplan, J., Fardeau, M., & Campbell, K. P. (1993) · Neuromuscular Disorders · doi:10.1016/0960-8966(93)90110-6 · Cited by 62
Loss of Strength and Functional Decline in Duchenne's Dystrophy
Allsop, K. G., & Ziter, F. A. (1981) · Archives of Neurology · doi:10.1001/archneur.1981.00510070040004 · Cited by 60
Steroids in Duchenne muscular dystrophy; Pilot study of a new low-dosage schedule
Sansome, A., Royston, P. J., & Dubowitz, V. (1993) · Neuromuscular Disorders · doi:10.1016/0960-8966(93)90117-3 · Cited by 59
A synergistic effect of glucocorticoids and insulin on the differentiation of myoblasts
Ball, E. H., & Sanwal, B. D. (1980) · Journal of Cellular Physiology · doi:10.1002/jcp.1041020105 · Cited by 59
Modulation by prednisolone of calcium handling in skeletal muscle cells
Metzinger, L., Passaquin, A., Leijendekker, W. J., Poindron, P., & Rüegg, U. T. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb15930.x · Cited by 59
Biggar, W. D., Bachrach, L. K., Henderson, R. C., Kalkwarf, H. J., Plotkin, H., & Wong, B. L. Y. (2005) · Neuromuscular Disorders · doi:10.1016/j.nmd.2004.09.010 · Cited by 58
Long-Term Steroid Therapy in Duchenne Muscular Dystrophy–Positive Results versus Side Effects
Schara, U., Mortier, & Mortier, W. (2001) · Journal of Clinical Neuromuscular Disease · doi:10.1097/00131402-200106000-00002 · Cited by 56
Dubowitz, V., Kinali, M., Main, M. L., Mercuri, E. M., & Francesco Muntoni, A. (2002) · European Journal of Paediatric Neurology · doi:10.1053/ejpn.2002.0583 · Cited by 56
Pasquini, F., Guérin, C., Blake, D. J., Davies, K. E., Karpati, G., & Holland, P. C. (1995) · Neuromuscular Disorders · doi:10.1016/0960-8966(94)00042-8 · Cited by 52
The Childhood Muscular Dystrophies: Diseases Sharing a Common Pathogenesis of Membrane Instability
Mendell, J. R., Sahenk, Z., & Prior, T. W. (1995) · Journal of Child Neurology · doi:10.1177/088307389501000219 · Cited by 47
Siegel, I. M., Je, M., & Rd, R. (1974) · PubMed · Cited by 32
Steroids in muscular dystrophy: where do we stand?
Dubrovsky, A. L., Angelini, C. I., Bonifati, D. M., Pegoraro, E., & Mesa, L. (1998) · Neuromuscular Disorders · doi:10.1016/s0960-8966(98)00047-9 · Cited by 31
Prednisolone in Duchenne muscular dystrophy.
Rahman, M. M., Hannan, M. A., Mondol, B. A., Bhoumick, N. B., & Haque, A. (2001) · PubMed · Cited by 30
Vandebrouck, C., Imbert, N., Duport, G., Cognard, C., & Raymond, G. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00418-8 · Cited by 29
A MANAGEMENT TRIAL FOR DUCHENNE CARDIOMYOPATHY
Ishikawa, Y., Bach, J. R., Ishikawa, Y., & Minami, R. (1995) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/00002060-199509000-00005 · Cited by 25
Dubowitz, V. (2000) · Neuromuscular Disorders · doi:10.1016/s0960-8966(00)00126-7 · Cited by 25
Prednisone for Duchenne muscular dystrophy
Dubowitz, V. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70050-8 · Cited by 21
Management of children: Pharmacological and physical
Heckmatt, J. Z., Rodillo, E., & Dubowitz, V. (1989) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a072358 · Cited by 12
[Steroid treatment of Duchenne's muscular dystrophy].
Carmen Luz Aviles, L., Carmen Gutiérrez, S., Fernando Novoa, S., Eugenia Gil, A., & Andrés Stuardo, L. (1982) · PubMed · Cited by 5
Medical management and treatment of muscular dystrophy
Manzur, A. Y. (2001) · doi:10.1093/oso/9780192632913.003.0012 · Cited by 5
Self-citation
Cited by
Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., Kaul, A., Kinnett, K., McDonald, C., Pandya, S., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70271-6 · Cited by 2,053
Evidence-based path to newborn screening for Duchenne muscular dystrophy
Mendell, J. R., Shilling, C., Leslie, N. D., Flanigan, K. M., al‐Dahhak, R., Gastier‐Foster, J., Kneile, K., Dunn, D. M., Duval, B., Aoyagi, A., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23528 · Cited by 813
Local Dystrophin Restoration with Antisense Oligonucleotide PRO051
van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J. T., Koop, K., van der Kooi, A. J., Goemans, N. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073108 · Cited by 781
Villalta, S. A., Nguyen, H. X., Deng, B., Gotoh, T., & Tidball, J. G. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn376 · Cited by 512
Corticosteroids for the treatment of Duchenne muscular dystrophy
Matthews, E., Brassington, R., Kuntzer, T., Jichi, F., & Manzur, A. Y. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003725.pub4 · Cited by 493
Self-citation
Metadata
- Authors
- Manzur, A., Kuntzer, T., Pike, M., & Swan, A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2004-04-19
- Issue
- 1
- Pages
- CD003725-CD003725
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W1888941810
- Cited by
- 539
- References
- 92
- Type
- reference entry
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.